Connect Biopharma Holdings Limited (CNTB)
Nasdaq · Healthcare · Biotechnology
$0.8979−3.14%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $56.5M
- 52-week range
- $0.886 – $3.82
- 52-week change
- −47.92%
- EPS (trailing)
- −$1.19
- Analyst rating
- 1.1 Strong buy
Fiscal year to Dec 2025
- Revenue
- $64K (−99.75%)
- Net income
- −$55.5M
- Operating margin
- −90740.6%
- Diluted EPS
- −$1.00
- Free cash flow
- −$51.6M
From the company’s annual report on SEC EDGAR.
About Connect Biopharma Holdings Limited
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.
Headquarters: San Diego, United States · 64 employees · connectbiopharm.com